92 related articles for article (PubMed ID: 31830896)
1. Transcriptome Analysis of MDA-MB-231 Cells Treated with Fumosorinone Isolated from Insect Pathogenic Fungi.
Liu Z; Tian Y; Chen Q; Zhang G; Li C; Luo DQ
Anticancer Agents Med Chem; 2020; 20(4):417-428. PubMed ID: 31830896
[TBL] [Abstract][Full Text] [Related]
2. Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).
Rong G; Kang H; Wang Y; Hai T; Sun H
PLoS One; 2013; 8(8):e70960. PubMed ID: 23951052
[TBL] [Abstract][Full Text] [Related]
3. Effect of combined treatment with lobaplatin and osthole on inducing apoptosis and inhibiting proliferation in human breast cancer MDA-MB-231 cells.
Liu N; Tian H; Zhang G; Sun N; Wang S
Med Oncol; 2021 Nov; 39(1):16. PubMed ID: 34837558
[TBL] [Abstract][Full Text] [Related]
4. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
5. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Tilli TM; Carels N; Tuszynski JA; Pasdar M
Oncotarget; 2016 Sep; 7(39):63189-63203. PubMed ID: 27527857
[TBL] [Abstract][Full Text] [Related]
6. [Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].
Fan J; Lu JS; Yin WJ; Lei W; Wu FY; Wu J; Hou YF; Li DQ; Di GH; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):886-9. PubMed ID: 17533736
[TBL] [Abstract][Full Text] [Related]
7. Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells.
Kim H; Kim HS; Moon WK
Toxicol Appl Pharmacol; 2019 Dec; 385():114814. PubMed ID: 31715268
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
[No Abstract] [Full Text] [Related]
9. Transcriptomic response of breast cancer cells to anacardic acid.
Schultz DJ; Krishna A; Vittitow SL; Alizadeh-Rad N; Muluhngwi P; Rouchka EC; Klinge CM
Sci Rep; 2018 May; 8(1):8063. PubMed ID: 29795261
[TBL] [Abstract][Full Text] [Related]
10. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
[TBL] [Abstract][Full Text] [Related]
11. A novel all-trans retinoid acid derivatives inhibits the migration of breast cancer cell lines MDA-MB-231 via myosin light chain kinase involving p38-MAPK pathway.
Wang B; Yan Y; Zhou J; Zhou Q; Gui S; Wang Y
Biomed Pharmacother; 2013 Jun; 67(5):357-62. PubMed ID: 23602051
[TBL] [Abstract][Full Text] [Related]
12. Identification of Carpesium cernuum extract as a tumor migration inhibitor based on its biological response profiling in breast cancer cells.
Dang H; Li H; Ma C; Wang Y; Tian J; Deng L; Wang D; Jing X; Luo K; Xing W; Cheng J; Guo H; Xie L
Phytomedicine; 2019 Nov; 64():153072. PubMed ID: 31480012
[TBL] [Abstract][Full Text] [Related]
13. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
14. VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.
Pu H; Zhang Q; Zhao C; Shi L; Wang Y; Wang J; Zhang M
Pathol Oncol Res; 2018 Jul; 24(3):557-565. PubMed ID: 28744693
[TBL] [Abstract][Full Text] [Related]
15. Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice.
Liu ZQ; Liu T; Chen C; Li MY; Wang ZY; Chen RS; Wei GX; Wang XY; Luo DQ
Toxicol Appl Pharmacol; 2015 May; 285(1):61-70. PubMed ID: 25796170
[TBL] [Abstract][Full Text] [Related]
16. DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage.
Greenshields AL; Power Coombs MR; Fernando W; Holbein BE; Hoskin DW
Biometals; 2019 Dec; 32(6):909-921. PubMed ID: 31624972
[TBL] [Abstract][Full Text] [Related]
17. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells.
Zhou T; Li Y; Yang L; Liu L; Ju Y; Li C
Oncol Rep; 2017 Jan; 37(1):388-398. PubMed ID: 27878264
[TBL] [Abstract][Full Text] [Related]
18. RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.
Bergamo A; Gerdol M; Lucafò M; Pelillo C; Battaglia M; Pallavicini A; Sava G
Metallomics; 2015 Oct; 7(10):1439-50. PubMed ID: 26338673
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome study of oleanolic acid in the inhibition of breast tumor growth based on high-throughput sequencing.
Liang Z; Pan R; Meng X; Su J; Guo Y; Wei G; Zhang Z; He K
Aging (Albany NY); 2021 Oct; 13(19):22883-22897. PubMed ID: 34607975
[TBL] [Abstract][Full Text] [Related]
20. Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancer.
Zhao F; Pan S; Gu Y; Guo S; Dai Q; Yu Y; Zhang W
PLoS One; 2014; 9(1):e86486. PubMed ID: 24489730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
